- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 04.11. | Nuvectis Pharma reports Q3 results | 1 | Seeking Alpha | ||
| 04.11. | Nuvectis Pharma, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 04.11. | Nuvectis Pharma, Inc. - 10-Q, Quarterly Report | - | SEC Filings | ||
| 28.10. | H.C. Wainwright bestätigt "Buy"-Rating für Nuvectis Pharma mit Kursziel von 10 US-Dollar | 16 | Investing.com Deutsch | ||
| 28.10. | H.C. Wainwright reiterates Buy rating on Nuvectis Pharma stock at $10 target | 1 | Investing.com | ||
| NUVECTIS PHARMA Aktie jetzt für 0€ handeln | |||||
| 25.09. | Nuvectis Pharma, Inc. - 8-K, Current Report | 3 | SEC Filings | ||
| 11.08. | Nuvectis Pharma, Inc.: Nuvectis Pharma Announces the Initiation of the Phase 1b Program for NXP900 | 449 | GlobeNewswire (Europe) | The Phase 1b program is designed to evaluate the clinical activity of NXP900 as a single agent in patients with advanced solid tumors whose cancers harbor specific genetic alterations, and in combination... ► Artikel lesen | |
| 05.08. | Nuvectis Pharma, Inc. - 10-Q, Quarterly Report | 2 | SEC Filings | ||
| 05.08. | Nuvectis Pharma, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 05.08. | Nuvectis Pharma GAAP EPS of -$0.30 | 3 | Seeking Alpha | ||
| 05.08. | Nuvectis Pharma, Inc. Reports Second Quarter 2025 Financial Results and Business Highlights | 258 | GlobeNewswire (Europe) | NXP900 becomes the lead drug candidate after successfully completing the Phase 1a dose escalation study in patients with advanced solid tumors and a drug-drug interaction study in healthy volunteers... ► Artikel lesen | |
| 04.08. | Nuvectis Pharma stock price target lowered to $10 at H.C. Wainwright | 1 | Investing.com | ||
| 31.07. | Nuvectis axes ovarian cancer program after seeing phase 1b data | 2 | FierceBiotech | ||
| 31.07. | Nuvectis halts NXP800 development for ovarian cancer, shifts focus | 2 | Investing.com | ||
| 31.07. | Nuvectis Pharma, Inc.: Nuvectis Pharma Provides Final Clinical Data Update from the NXP800 Phase 1b Study in Ovarian Cancer and Reports Completion of the NXP900 Phase 1a Dose Escalation Study | 159 | GlobeNewswire (Europe) | Available data from 13 patients with recurrent, platinum resistant, ARID1a-mutated ovarian cancer treated with 75 mg/day in the NXP800 Phase 1b study includes 2 partial responses and 3 stable diseases... ► Artikel lesen | |
| 08.07. | Nuvectis reports positive drug interaction study for cancer drug NXP900 | 1 | Investing.com | ||
| 13.06. | Nuvectis Pharma, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 06.05. | Nuvectis Pharma, Inc. Reports First Quarter 2025 Financial Results and Business Highlights | 141 | GlobeNewswire (Europe) | NXP900 clinical data presentation from the Phase 1a dose escalation study at the 2025 American Association for Cancer Research (AACR) conference demonstrated robust pharmacodynamic response and acceptable... ► Artikel lesen |
18 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| QIAGEN | 38,070 | +0,83 % | Qiagen auf der Jefferies-Konferenz: Wachstumskurs trotz Herausforderungen | ||
| OLEMA PHARMACEUTICALS | 19,460 | 0,00 % | Biotech-Party! Olema-Aktie explodiert über 136 Prozent - die Hintergründe | Prämie dank Übernahme? Spektakuläre Studienergebnisse? Es ist keine Seltenheit, dass Biotech-Titel aus dem Stand an einem Tag prozentual dreistellig an Wert gewinnen können. Bei Olema Pharmaceuticals... ► Artikel lesen | |
| NUVATION BIO | 7,160 | 0,00 % | Nuvation Bio rises as B. Riley starts at Buy on launch trajectory for lead drug | ||
| NUVALENT | 107,08 | +2,72 % | Nuvalent, Inc.: Nuvalent Announces Positive Topline Pivotal Data from ALKOVE-1 Clinical Trial of Neladalkib for TKI Pre-treated Patients with Advanced ALK-positive NSCLC | In 253 ALK TKI pre-treated patients, ORR by BICR was 31% (95% CI: 26, 37), with initial estimated durability of response of 64% and 53% at the 12-month and 18-month... ► Artikel lesen | |
| INHIBRX BIOSCIENCES | 82,14 | +5,58 % | Inhibrx Biosciences, Inc.: Inhibrx Reports Third Quarter 2025 Financial Results | SAN DIEGO, Nov. 14, 2025 /PRNewswire/ -- Inhibrx Biosciences, Inc. (Nasdaq: INBX) ("Inhibrx" or the "Company") today reported financial results for the third quarter... ► Artikel lesen | |
| BIONTECH | 88,00 | +0,06 % | BioNTech Aktie: Große Gewinne? - Bayer, Evotec, Hensoldt, Kontron und Rheinmetall im Marktbericht Börse Frankfurt | Wo ist am Aktienmarkt etwas los, welche Themen interessieren Anleger derzeit besonders? Vor allem für Trader ist es wichtig zu wissen, wo "die Musik spielt" und welche Themen an der Börse aktuell besonders... ► Artikel lesen | |
| AVIDITY BIOSCIENCES | 70,88 | +0,05 % | Avidity startet Programm für frühzeitigen Zugang zu DMD44-Therapie | ||
| ARCUTIS BIOTHERAPEUTICS | 27,900 | 0,00 % | Arcutis Biotherapeutics, Inc.: FDA Accepts Supplemental New Drug Application for Arcutis' ZORYVE (roflumilast) Cream 0.3% for the Treatment of Plaque Psoriasis in Children Ages 2 to 5 | Prescription Drug User Fee Act (PDUFA) target action date set for June 29, 2026If approved, ZORYVE cream 0.3% would be the first and only topical PDE4 inhibitor indicated for plaque psoriasis in children... ► Artikel lesen | |
| MINERALYS THERAPEUTICS | 42,050 | 0,00 % | Mineralys Therapeutic: Aktie gibt nach umfangreichen Insiderverkäufen nach | ||
| ADMA BIOLOGICS | 15,950 | +1,69 % | ADMA Biologics, Inc.: ADMA Biologics Announces Second Quarter 2025 Financial Results and Provides Business Update | 2Q 2025 Total Revenue of $122.0 Million, a 14% YoY Increase, and a 29% YoY Increase Excluding a Prior Year Non-Recurring Item 2Q 2025 GAAP Net Income of $34.2 Million, a 7% YoY Increase 2Q 2025 Adjusted... ► Artikel lesen | |
| COGENT BIOSCIENCES | 34,940 | 0,00 % | Cogent Biosciences, Inc. - 8-K, Current Report | ||
| STRUCTURE THERAPEUTICS | 36,500 | +5,80 % | Structure Therapeutics Inc.: Structure Therapeutics Reports Third Quarter 2025 Financial Results and Recent Highlights | Topline 36-week data from oral small molecule GLP-1 receptor agonist aleniglipron ACCESS and ACCESS II studies on track for readouts by year-end 2025 Oral small molecule amylin receptor agonist (ACCG-2671)... ► Artikel lesen | |
| EVOTEC | 5,162 | -0,77 % | Eilmeldung am Abend: EVOTEC SE zeigt unerwartete Stärke | ||
| PRAXIS PRECISION MEDICINES | 189,82 | 0,00 % | Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | BOSTON, Oct. 02, 2025 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (Nasdaq: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies... ► Artikel lesen | |
| RECURSION PHARMACEUTICALS | 4,035 | 0,00 % | Is Recursion Pharmaceuticals a Meme Stock? |
NUVECTIS PHARMA INC gehört der Branche Biotechnologie an. Die relative Kursveränderung beträgt aktuell 0,00 % bei einem Aktienkurs von 6,000 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu NUVECTIS PHARMA INC finden Sie auf Wallstreet Online.